Sign In
Buy CELU
$1.06
-0.0100 (-0.93%)
At Close: Jun 02, 2026
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
02:10pm, Thursday, 18'th Dec 2025
FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
08:00am, Thursday, 30'th Oct 2025
FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,
FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases,
Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compli
Celularity Receives Nasdaq Notice Regarding Form 10-Q
05:30pm, Friday, 22'nd Aug 2025
FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on addressing age-rel
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
08:00am, Monday, 18'th Aug 2025
Retired all principal and accrued interest owed its two senior secured lenders, Resorts World Inc. Pte. Ltd., or RWI, and C.V.
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
08:30am, Wednesday, 09'th Jul 2025
FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
08:30am, Tuesday, 01'st Jul 2025
New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 202
Celularity Announces Chief Financial Officer Transition
04:15pm, Tuesday, 10'th Jun 2025
Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide out
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
08:00am, Monday, 02'nd Jun 2025
Highlights the unique potential of Celularity's proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative m
Celularity Receives Nasdaq Notice Regarding Form 10-Q
05:30pm, Friday, 30'th May 2025
FLORHAM PARK, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that on May 2
Celularity Announces Full Year 2024 Operating and Financial Results
09:15am, Friday, 09'th May 2025
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024,
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
05:30pm, Friday, 25'th Apr 2025
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
08:00am, Monday, 14'th Apr 2025
Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers Action delays to January 1, 2026,
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
08:00am, Tuesday, 25'th Feb 2025
Natalin and Acelagraft™ are the latest additions to Celularity's portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds Natalin and Acelagr
